The U.S. in vitro diagnostics market is estimated to grow at a compound annual growth rate of 4.9% during the forecast period of 2018 to 2023. The market revenue (in USD million) is estimated from 2017 to 2023. In vitro diagnostics market can be segmented on the basis of type, techniques, applications and end users. By type the market is segmented into instruments, reagents, data management software and services. By in vitro diagnostics techniques, the market is segmented into immunoassay, clinical chemistry, microbiology, molecular diagnostics, hematology, coagulation & hemostasis and others. The major applications studied in the report are, infectious diseases, cancer/oncology, endocrinology, cardiology, diabetes, nephrology and others. Major end users of the in vitro diagnostics technologies are hospitals, clinical laboratories, academic & research institutes, physician offices, patient-self testing and others.
The United States in vitro diagnostics market is dominated by key players such as Abbott Diagnostics, Alere, Beckman Coulter, Becton Dickinson, Biomerieux, Danaher Corporation, Hologic, Ortho-Clinical Diagnostics, QIAGEN, Roche Diagnostics, Siemens Healthcare Diagnostics, Sysmex Corporation and Thermo Fisher Scientific.
The company profile of the leading players include key financials, detailed product portfolio, last 4 years & recent developments etc. The report also covers competitive landscape such as merger and acquisitions, new product launches, agreements, new business channels etc. of the United States in vitro diagnostics market of last 4 years.
The main factors driving the United States in vitro diagnostics market are growing population and the prevalence of chronic and contagious diseases, growing preference of point-of-care testing diagnostics devices and government initiatives to promote healthcare etc. The growth restraints of the market are mainly due to the unfavorable reimbursement, stringent regulatory framework etc.